Get the Daily Brief
Latest Biotech News
Methylation blood test moves to Pitt: preclinical study for pancreatic cancer
Singlera Genomics and Breakthrough Genomics launched a preclinical collaboration with the University of Pittsburgh to evaluate the BT‑Reveal early pancreatic cancer test, a methylation‑based...
JAX completes NYSCF acquisition – unified nonprofit launches in New York
The Jackson Laboratory completed its acquisition of the New York Stem Cell Foundation and held a launch event at NYSCF’s Manhattan campus to mark a unified nonprofit research organization. The...
BC Platforms adds GeneVault data – 48M patient multimodal cohort
BC Platforms signed an agreement with GeneVault to integrate multimodal genomic, phenomic and clinical datasets from approximately 48 million patients into BC Unify. The datasets cover...
Harbour inks $90M antibody pact with BMS – multi‑specifics and China strategy
Harbour BioMed and Bristol Myers Squibb signed a discovery and development collaboration centered on next‑generation multi‑specific antibody therapeutics. Harbour will receive $90 million upfront...
BioMarin pays $4.8B for Amicus — rare‑disease portfolio expands
BioMarin agreed to acquire Amicus Therapeutics in an all‑cash deal that values Amicus at roughly $4.8 billion. The boards approved the transaction; BioMarin will take on Amicus’ approved therapies...
Patient deaths prompt partial hold: Merck, Daiichi ADC trial paused
Regulators and sponsors paused enrollment in a Phase III study testing an antibody‑drug conjugate (ADCs) after a cluster of fatal events. Daiichi Sankyo voluntarily put recruitment on hold in the...
FDA greenlights Myqorzo: Cytokinetics lands first US approval
The FDA approved Cytokinetics’ Myqorzo to treat obstructive hypertrophic cardiomyopathy, giving the company its first U.S. drug approval after decades of development. Myqorzo will launch...
Epigenovo targets clinics: single‑cell chromatin assay for FFPE tissue
Epigenovo, a Uppsala University spinout, is commercializing scFFPE‑ATAC — a single‑cell chromatin accessibility assay compatible with formalin‑fixed paraffin‑embedded (FFPE) samples. The startup...
Parse and Codebreaker pair single‑cell scale with variant libraries
Parse Biosciences and Codebreaker Labs launched a collaboration to pair Codebreaker’s engineered variant libraries with Parse’s single‑cell transcriptomics platform to experimentally map how...
Galux and Boehringer ink AI design pact: purposeful proteins next
Galux signed a research agreement with Boehringer Ingelheim to test AI‑driven protein design for therapeutic use cases. The collaboration will validate AI‑designed, purpose‑specific proteins...
Bruker settles with AbCellera — $36M plus royalties to end IP fight
Bruker agreed to pay AbCellera $36 million and royalties to resolve patent litigation tied to microfluidic single‑cell platforms. The settlement covers Bruker’s Beacon‑derived Optofluidic platform...
JAX and NYSCF unify — nonprofit engine for genomics and stem cells
The Jackson Laboratory completed its acquisition of the New York Stem Cell Foundation and formally launched the unified nonprofit organization in New York. JAX leaders said the integration pairs...
Nonprofit rescues abandoned gene therapy — can the model scale?
A nonprofit effort brought an orphaned rare‑disease gene therapy to market by rescuing development and facilitating access, according to BioCentury’s reporting. The case involved Fondazione...
FDA issues two Form 483s to Catalent’s Maryland gene‑therapy sites
The FDA issued two Form 483 observations to Catalent’s Maryland facilities that manufacture gene‑therapy products prior to a round of mass layoffs at the sites. The notices relate to manufacturing...
BioMarin buys Amicus for $4.8B — rare-disease portfolio enlarged
BioMarin agreed to acquire Amicus Therapeutics for $4.8 billion, buying two approved therapies for Fabry and Pompe disease and gaining U.S. rights to a late‑stage candidate for focal segmental...
FDA clears Cytokinetics’ heart drug — company gets first U.S. approval
The FDA approved Cytokinetics’ Myqorzo (first U.S. approval), a therapy for obstructive hypertrophic cardiomyopathy, marking the company’s first marketed product after nearly three decades....
Partial hold on Merck‑Daiichi ADC trial after fatal events
Daiichi Sankyo and Merck paused enrollment and the FDA placed a partial hold on the Phase III IDeate‑Lung02 study of the ADC ifinatamab deruxtecan following a higher‑than‑anticipated incidence of...
CEPI backs Moderna H5 mRNA program — Phase 3 push funded
The Coalition for Epidemic Preparedness Innovations (CEPI) agreed to fund Moderna’s mRNA H5 avian influenza vaccine candidate with up to $54.3 million to advance the program into Phase 3 testing....
Single‑cell assays and variant mapping: tools for translation
Two technology stories spotlight efforts to scale single‑cell and variant‑effect assays for translational discovery. Swedish spinout Epigenovo is commercializing scFFPE‑ATAC, a single‑cell...
Galux and Boehringer ink AI protein‑design pact
Galux, a South Korean AI‑driven protein therapeutics startup, signed a research agreement with Boehringer Ingelheim to explore AI‑powered precision protein design. The collaboration will evaluate...